139 related articles for article (PubMed ID: 38272149)
1. Why does HER2-positive breast cancer metastasize to the brain and what can we do about it?
Xu D; Hu Z; Wang K; Hu S; Zhou Y; Zhang S; Chen Y; Pan T
Crit Rev Oncol Hematol; 2024 Mar; 195():104269. PubMed ID: 38272149
[TBL] [Abstract][Full Text] [Related]
2. Molecular and cellular mechanisms underlying brain metastasis of breast cancer.
Hosonaga M; Saya H; Arima Y
Cancer Metastasis Rev; 2020 Sep; 39(3):711-720. PubMed ID: 32399646
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
[TBL] [Abstract][Full Text] [Related]
4. Cooperation of neurotrophin receptor TrkB and Her2 in breast cancer cells facilitates brain metastases.
Choy C; Ansari KI; Neman J; Hsu S; Duenas MJ; Li H; Vaidehi N; Jandial R
Breast Cancer Res; 2017 Apr; 19(1):51. PubMed ID: 28446206
[TBL] [Abstract][Full Text] [Related]
5. New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
Yamamura J; Kamigaki S; Fujita J; Osato H; Manabe H; Tanaka Y; Shinzaki W; Hashimoto Y; Komoike Y
BMC Cancer; 2021 Apr; 21(1):476. PubMed ID: 33926418
[TBL] [Abstract][Full Text] [Related]
6. EGFR and HER2 signaling in breast cancer brain metastasis.
Sirkisoon SR; Carpenter RL; Rimkus T; Miller L; Metheny-Barlow L; Lo HW
Front Biosci (Elite Ed); 2016 Jan; 8(2):245-63. PubMed ID: 26709660
[TBL] [Abstract][Full Text] [Related]
7. Outcomes and Prognostic Factors in HER2-Positive Metastatic Breast Cancer Patients Who Had Developed Brain Metastasis in the Treatment Process.
Dogan I; Kizildag I; Özkurt S; Ibis K; Vatansever S; Saip P; Aydiner A
Oncology; 2023; 101(4):262-269. PubMed ID: 36809751
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.
Hayashi N; Niikura N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Yamauchi H; Saji S; Iwata H
Breast Cancer Res Treat; 2015 Jan; 149(1):277-84. PubMed ID: 25528021
[TBL] [Abstract][Full Text] [Related]
9. Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases.
Liu MC; Cortés J; O'Shaughnessy J
Cancer Metastasis Rev; 2016 Jun; 35(2):323-32. PubMed ID: 27023712
[TBL] [Abstract][Full Text] [Related]
10. Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis.
Honkanen TJ; Luukkainen MEK; Tikkanen A; Karihtala P; Mäkinen M; Väyrynen JP; Koivunen JP
Breast Cancer Res Treat; 2022 Jan; 191(2):443-450. PubMed ID: 34817749
[TBL] [Abstract][Full Text] [Related]
11. FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis.
Cordero A; Kanojia D; Miska J; Panek WK; Xiao A; Han Y; Bonamici N; Zhou W; Xiao T; Wu M; Ahmed AU; Lesniak MS
Oncogene; 2019 Sep; 38(37):6445-6460. PubMed ID: 31324889
[TBL] [Abstract][Full Text] [Related]
12. Treatment of brain metastases in patients with HER2+ breast cancer.
Bravo Marques JM
Adv Ther; 2009 Jul; 26 Suppl 1():S18-26. PubMed ID: 19669638
[TBL] [Abstract][Full Text] [Related]
13. ER
Arciero CA; Guo Y; Jiang R; Behera M; O'Regan R; Peng L; Li X
Clin Breast Cancer; 2019 Aug; 19(4):236-245. PubMed ID: 30846407
[TBL] [Abstract][Full Text] [Related]
14. Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis.
Louie E; Chen XF; Coomes A; Ji K; Tsirka S; Chen EI
Oncogene; 2013 Aug; 32(35):4064-77. PubMed ID: 23001042
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
16. Astrocyte-induced Reelin expression drives proliferation of Her2
Jandial R; Choy C; Levy DM; Chen MY; Ansari KI
Clin Exp Metastasis; 2017 Feb; 34(2):185-196. PubMed ID: 28210910
[TBL] [Abstract][Full Text] [Related]
17. Brain metastasis in breast cancer: a comprehensive literature review.
Rostami R; Mittal S; Rostami P; Tavassoli F; Jabbari B
J Neurooncol; 2016 May; 127(3):407-14. PubMed ID: 26909695
[TBL] [Abstract][Full Text] [Related]
18. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.
Murthy P; Kidwell KM; Schott AF; Merajver SD; Griggs JJ; Smerage JD; Van Poznak CH; Wicha MS; Hayes DF; Henry NL
Breast Cancer Res Treat; 2016 Feb; 155(3):589-95. PubMed ID: 26875184
[TBL] [Abstract][Full Text] [Related]
19. Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis.
Jung J; Lee SH; Park M; Youn JH; Shin SH; Gwak HS; Yoo H
J Neurooncol; 2018 Apr; 137(2):295-302. PubMed ID: 29260362
[TBL] [Abstract][Full Text] [Related]
20. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
McMullin RP; Wittner BS; Yang C; Denton-Schneider BR; Hicks D; Singavarapu R; Moulis S; Lee J; Akbari MR; Narod SA; Aldape KD; Steeg PS; Ramaswamy S; Sgroi DC
Breast Cancer Res; 2014 Mar; 16(2):R25. PubMed ID: 24625110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
